Micreos Initiates P-I/IIa Study Evaluating XZ.700 as the World’s First Endolysin Therapy for Atopic Dermatitis

 Micreos Initiates P-I/IIa Study Evaluating XZ.700 as the World’s First Endolysin Therapy for Atopic Dermatitis

Micreos Initiates P-I/IIa Study Evaluating XZ.700 as the World’s First Endolysin Therapy for Atopic Dermatitis

Shots:

  • The company has enrolled the first patient in P-I/IIa Study assessing XZ.700 in 48 patients with mild to moderate AD in the Netherlands. This marks the world’s 1st evaluation of a pharmaceutical endolysin for topical use in humans
  • The patients will be treated for 14 days with a cream containing XZ.700 at 3 different concentrations vs PBO. The company expects to complete the study and report the results trial by the end of 2021
  • XZ.700 is an endolysin targeting S. aureus, including the antibiotic-resistant MRSA, while preserving Staphylococcus epidermidis, that is beneficial on the skin and helps in healing wounds. XZ.700 targets multiple indications including AD, diabetic wound infections, and cutaneous T-cell lymphoma

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Micreos

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post